Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032
about
Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteersBactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cellsCyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteriaEffects of daptomycin and vancomycin on tobramycin nephrotoxicity in ratsInfluence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicityTranscriptome analysis of the responses of Staphylococcus aureus to antimicrobial peptides and characterization of the roles of vraDE and vraSR in antimicrobial resistance.In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.Transferable vancomycin and teicoplanin resistance in Enterococcus faecium.In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Natural products to drugs: daptomycin and related lipopeptide antibiotics.Mechanism of action of oritavancin and related glycopeptide antibiotics.Identification of daptomycin-binding proteins in the membrane of Enterococcus hiraeResistance of enterococci to glycopeptides.In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteriaIn vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria.Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activityEx vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycinSusceptibility to hydrophobic molecules and phospholipid composition in Pasteurella multocida and Actinobacillus lignieresiiMolecular basis of the non-beta-lactamase-mediated resistance to beta-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada.The discovery of cell wall active antibacterial antibiotics.Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization.Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.Use of multivariate analysis to compare antimicrobial agents on the basis of in vitro activity dataEffects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococciDaptomycin disrupts membrane potential in growing Staphylococcus aureus.Effect of beta-lactams on peptidoglycan metabolism of Haemophilus influenzae grown in animals.Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains.Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.Therapeutic update on glycopeptide and lipopeptide antibiotics.Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic.Inhibition of peptidoglycan biosynthesis by ramoplanin.Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance.Knockout of the two ldh genes has a major impact on peptidoglycan precursor synthesis in Lactobacillus plantarum.Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis.Inhibition of membrane potential-dependent amino acid transport by daptomycin.In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate.
P2860
Q24679375-9D9310E0-3542-4345-B2B3-3ABAA31A58CFQ24682375-13CCB320-796F-41A9-9AB6-FB19078FF5B1Q26863225-F701A8A5-157D-4667-8F81-D19A1F359E77Q28330353-94E02787-1619-45F9-8A7D-9B823F867383Q28343011-7F2CC069-77C4-48E8-88FC-13025E9647CFQ33502861-5D265123-A76D-4372-B02E-2B457DD52198Q33979251-44A412E8-4136-4930-9B25-6D575FA4B7FDQ33981666-36BF86A8-D7B5-45F2-9C2F-F17E4B1D4BE3Q34042099-90CC84F6-F8AD-4BBC-BBB6-4DC77E659B3DQ34110412-FEAFEF01-D4AC-4AE5-A7AD-E3793BF5BE68Q34470713-A6E7D903-B280-4DD0-8184-2E2333DCE9C2Q35066202-8B98A88D-1FBB-47CB-A769-FF009BD82ADFQ35118472-9187E27A-7F15-4515-847A-9FF39362B95AQ35284014-70BC3FB2-A66E-4BE0-9C69-0E5F729128C6Q35307059-FF8218EF-AEF7-43E8-B9AE-7D83AA174AE9Q35345381-754F396E-7E94-4FEF-9673-737142E01DF7Q35352499-367B15BB-2B13-4121-BBFA-DD93A8D7D545Q35355587-FDC88A7B-B508-4893-8A6F-95632FCFA98DQ35563861-32F89B33-9D52-484C-A5E4-28E591A297B4Q35885262-5667AAFD-7E2D-46FA-9518-707FF653545BQ36335002-37B63320-0D12-4810-B098-6C2B8FFBA6F0Q36482900-DBEBAF75-3361-4A14-9008-8220D826F1CFQ36565462-F1F38F72-8B51-45E9-8559-3C0040AED792Q36751113-0F6089AA-308B-4D74-9487-4731EE8942E1Q36752594-DA426F6B-AC7F-40FF-AF4F-34C9FB92AB12Q36756893-A89A0E84-6517-44EA-82B8-A30EAE76744EQ36757748-33DF7FBB-6902-43C2-91F9-4312BEA5CB03Q36777821-9D06A3DA-29A3-4947-A11D-683C5FDE2DB3Q37417749-FD54C45E-7437-401C-808D-CE80CC7BF0C6Q38360418-0F5C9235-AEA4-469A-9B67-4104D9CFD596Q39291062-A79507D5-6697-4069-A942-045E72C239D7Q39782968-9B805FAD-50E8-45EC-B1A6-85A31A431CC0Q39815497-FF214C84-159E-4CCF-BA57-DDBD05327639Q39816283-E05C1086-9979-41F4-91DC-2D862750D404Q39818976-06D0A089-B9ED-46F0-8615-DA200ED642F1Q39842733-D6C6EF28-C89F-40F8-9C1E-7441E1BC3D51Q40085787-8BF8A570-7344-4F9D-BD5B-92DD9A333468Q40088405-E66080C5-D6C5-4F9E-9CE7-66765EB2F4E6Q40088863-DD31C40A-5C41-464B-AC6E-24E75BEF1875Q42140912-E0567302-D921-463E-BD69-159CFBB6399B
P2860
Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032
@en
Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.
@nl
type
label
Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032
@en
Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.
@nl
prefLabel
Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032
@en
Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.
@nl
P2093
P2860
P356
P1476
Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032
@en
P2093
P2860
P304
P356
10.1128/AAC.31.7.1093
P407
P577
1987-07-01T00:00:00Z